Document Detail


Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?
MedLine Citation:
PMID:  7599349     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients suffering from the severe complications associated with both insulin- (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM): nephropathy, retinopathy, neuropathy, and atherosclerosis are still largely left without a prospect of an efficient treatment. This is the case even if it has been assumed for decades and now finally proved by the results from the Diabetes Control and Complications Trial (DCCT) that hyperglycemia is the single main cause of these complications. Improved glycemic control as a result of intensive insulin treatment has the potential to reduce the incidence and progression of complications, but implementation and monitoring of improved glycemic control in all groups of IDDM and NIDDM patients in different communities will be difficult and expensive. Results from the recently terminated DCCT have shown that even with intensive insulin treatment, there will be a significant burden of complications on the diabetic population. It will, therefore, still be of immense importance for the long-term quality of life for the diabetic patient that additional possibilities are developed for prevention and intervention against diabetic complications. Almost two decades of research, animal model testing, and clinical trials have been conducted on various efficient aldose reductase inhibitors. Now the concept of inhibition of formation of advanced glycosylation endproducts on proteins and lipids resulting from extra- and intracellular hyperglycemia is entering the scene as an alternative or perhaps supplementary approach to reduce the occurrence of diabetic complications. An overview of the results from these two fields of research and associated drug-development programs will be presented along with thoughts on possible future developments.
Authors:
E Boel; J Selmer; H J Flodgaard; T Jensen
Related Documents :
24038369 - Glycaemic control in children with neonatal diabetes and type 1 diabetes in vietnam.
24821389 - Association between diabetic ketoacidosis hospitalizations and driving distance to outp...
24775839 - Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy...
20495239 - Determination of trace element levels in human blood serum from patients with type ii d...
23121699 - Diabetic retinopathy screening and teleophthalmology.
9796849 - Vascular complications of diabetes mellitus: what role for phospholipid-binding antibod...
12086949 - Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism...
23483669 - Mechanisms of disease: inflammasome activation and the development of type 2 diabetes.
19466549 - Mitochondria mediated cell death in diabetes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of diabetes and its complications     Volume:  9     ISSN:  1056-8727     ISO Abbreviation:  J. Diabetes Complicat.     Publication Date:    1995 Apr-Jun
Date Detail:
Created Date:  1995-08-10     Completed Date:  1995-08-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9204583     Medline TA:  J Diabetes Complications     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  104-29     Citation Subset:  IM    
Affiliation:
Novo Nordisk, Bagsvaerd, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldehyde Reductase / antagonists & inhibitors*
Animals
Arteriosclerosis / drug therapy
Clinical Trials as Topic
Diabetes Mellitus, Type 1 / drug therapy,  physiopathology*
Diabetes Mellitus, Type 2 / drug therapy,  physiopathology*
Diabetic Angiopathies / drug therapy*
Diabetic Nephropathies / drug therapy*
Diabetic Neuropathies / drug therapy*
Diabetic Retinopathy / drug therapy*
Glycosylation End Products, Advanced / antagonists & inhibitors*
Humans
Insulin / therapeutic use
Chemical
Reg. No./Substance:
0/Glycosylation End Products, Advanced; 11061-68-0/Insulin; EC 1.1.1.21/Aldehyde Reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Proliferation and differentiation of the small intestinal epithelium: from Petri dish to bedside.
Next Document:  Cytosolic Ca profile of resting and thrombin-stimulated platelets from black women with NIDDM.